{"name":"Biocon Biologics UK Ltd","slug":"biocon-biologics-uk-ltd","ticker":"","exchange":"","domain":"","description":"","hq":"","founded":0,"employees":"","ceo":"","sector":"","stockPrice":0,"stockChange":0,"stockChangePercent":0,"marketCap":"","metrics":{"revenue":0,"revenueGrowth":0,"grossMargin":0,"rdSpend":0,"netIncome":0,"cash":0,"dividendYield":0,"peRatio":0,"fiscalYear":"FY2026"},"revenueBreakdown":[],"timeline":[{"date":"2026-07-28","label":"Q2 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2026-10-28","label":"Q3 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-01-28","label":"Q4 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-04-28","label":"Q1 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-07-28","label":"Q2 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-10-28","label":"Q3 2027 Earnings","type":"earnings","sentiment":"neutral"}],"diseaseAreas":[{"name":"Other","slug":"other","revenue":0,"percentOfTotal":0,"drugCount":2,"colorKey":"immunology","drugs":[{"name":"Bmab1200","genericName":"Bmab1200","slug":"bmab1200","indication":"Other","status":"phase_3"},{"name":"Bmab 1000","genericName":"Bmab 1000","slug":"bmab-1000","indication":"Other","status":"phase_3"}]},{"name":"Immunology","slug":"immunology","revenue":0,"percentOfTotal":0,"drugCount":1,"colorKey":"oncology","drugs":[{"name":"Stelara","genericName":"Stelara","slug":"stelara","indication":"Crohn's disease","status":"marketed"}]},{"name":"Oncology","slug":"oncology","revenue":0,"percentOfTotal":0,"drugCount":1,"colorKey":"cardiovascular","drugs":[{"name":"Herceptin Hylecta®","genericName":"Herceptin Hylecta®","slug":"herceptin-hylecta","indication":"HER2-positive early breast cancer (adjuvant and neoadjuvant treatment)","status":"marketed"}]}],"pipeline":[{"name":"Stelara","genericName":"Stelara","slug":"stelara","phase":"marketed","mechanism":"Stelara binds to the p40 subunit of IL-12 and IL-23, reducing inflammation in autoimmune diseases.","indications":["Crohn's disease","Plaque psoriasis","Psoriasis","Psoriasis with arthropathy","Ulcerative colitis"],"catalyst":""},{"name":"Bmab1200","genericName":"Bmab1200","slug":"bmab1200","phase":"phase_3","mechanism":"Bmab1200 is a monoclonal antibody targeting a specific immune or disease-related antigen to modulate immune response or block pathogenic signaling.","indications":[],"catalyst":""},{"name":"Bmab 1000","genericName":"Bmab 1000","slug":"bmab-1000","phase":"phase_3","mechanism":"Bmab 1000 is a monoclonal antibody targeting a specific molecular pathway, though the exact target is not publicly disclosed in available sources.","indications":[],"catalyst":""},{"name":"Herceptin Hylecta®","genericName":"Herceptin Hylecta®","slug":"herceptin-hylecta","phase":"marketed","mechanism":"Herceptin Hylecta is a subcutaneous formulation of trastuzumab that binds to HER2 receptors on cancer cells to block growth signaling and trigger immune-mediated cell death.","indications":["HER2-positive early breast cancer (adjuvant and neoadjuvant treatment)","HER2-positive metastatic breast cancer","HER2-positive gastric or gastroesophageal junction adenocarcinoma"],"catalyst":""}],"recentEvents":[],"realNews":[{"url":"https://news.google.com/rss/articles/CBMilgFBVV95cUxOQmdMT3NHWUdCTC1wbzNoejRLNW1UZ2RTX0JjN3dqZ0lyRlA5ZU1vQi1neHlocTBQei05MGdpbjZSeThrZDJvS1d1WXJ1Um1wNWFIOUVMMlVjN1UybEstZjR3R1B3M3FmamVWVVhGQ2thUHR0QndxZzVYV2FxVi1aY3hIV3NtZFRnVlF5RWpHMk1fSVVJeEE?oc=5","date":"2026-02-16","type":"regulatory","source":"themalaysianreserve.com","summary":"Duopharma secures two MOH contacts worth RM118m - themalaysianreserve.com","headline":"Duopharma secures two MOH contacts worth RM118m","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiggFBVV95cUxQQzRRaWxaX0Y4TVVjdVdRREgyYjFaVDZRMjJBak1mSGxUdC1WOWV5b0VGUW90RGcyQ05fcXh4RkNyRzdvSmJQMy1fc1M5UmNPWEFGZDlkalJXRmEyYTlvTlpuMWd6RTF0d1JPZzJHY0lZWkE5MjZ5MVpTbzRVOHJnczBR?oc=5","date":"2026-01-22","type":"regulatory","source":"JD Supra","summary":"How the U.S. Compares to Europe on Biosimilar Approvals and Products In the Pipeline - Updated January 22, 2026 - JD Supra","headline":"How the U.S. Compares to Europe on Biosimilar Approvals and Products In the Pipeline - Updated January 22, 2026","sentiment":"positive"},{"url":"https://news.google.com/rss/articles/CBMipAFBVV95cUxNX2tNSkdyU2RNT1YwUk14ZVJPTFNxS3VvWFZwazc2YTNIdlludjRTdnVUUEhCVFk1MzN1SUxDS2FSa2Rqbk9kSXh6RGFKU2RVU2JienFWa2Eya2wtVTRjZ0xxcU1NZFptdjZJUnhmYVZ6THlyemhONGQxQ3czbVAtcHpRQTdodklOTElHTFozU19makgtQ1UtWGx5UU1OaFgxdWp6Qw?oc=5","date":"2025-12-29","type":"patent","source":"The Pharma Letter","summary":"Biocon secures global rights to biosimilar adalimumab - The Pharma Letter","headline":"Biocon secures global rights to biosimilar adalimumab","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMingFBVV95cUxQb2NlakRwSnBOVjZaMFd0ZVNQaUhtdVFqYlkyZElGYThDWU1COWlCRXd6NU5KdDFncVRiY2FDVnRhMWZ6ZE5BcnlSR3h2LUxrdDRZTVMyRnpCYTk2SThzNDd1dUd3NEtmTkFWWVZZaU1HdUY0WktjbEtTTFZUMkgyem4xaEREZENkbVpJTWoyV2V1WDIwRjRWOUt4eFdoZ9IBVkFVX3lxTFAxZmE5MDFRME1BRE1rVmRCakJZMXFCSFY5X0x4VmoyVEtPazVTN08zZzR6QkFwanlWT3lnVWZfMDBWZ29hWmF6ZkRqUzRZV2FXemhBdlFR?oc=5","date":"2025-11-28","type":"patent","source":"Law360","summary":"Regeneron Claims Biocon Drug Mimics Its Patented Medicine - Law360","headline":"Regeneron Claims Biocon Drug Mimics Its Patented Medicine - Law360","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMingFBVV95cUxOX2ZmcjRzYndPekJPVXdENnR0RllpVWM5Y0VneXRjblRXVmVhel9lZzIxVkRkaXhVZEc3LS1mYmN6N3ZhQlRBUEhSck5GZlFFekRQd0JRamJKSWEtbVdHRW9nb05SRGF1V1NSX2NvdVhJVHluT0tnM2JIN1ROaHA2amlvYml3bE9FaWh5N1N2eDc1VzRVRUdHRUw2X1BPd9IBVkFVX3lxTE9ZYlRkbXliRkUyTzM2ZTRUeXpKaHlRR1VzbFA0RlZOQ1ZuQzlJNzY0MUFMbFBHS0ptRkZNTHk3MkZBTW1YV21VNnJDOGY2QjhOZTdoelpn?oc=5","date":"2025-11-14","type":"patent","source":"Law360","summary":"Biocon Challenges Regeneron Over UK Retinal Pharma Patent - Law360","headline":"Biocon Challenges Regeneron Over UK Retinal Pharma Patent - Law360","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMifkFVX3lxTFAxTXNtR1lrU3JXcGFSM2ZrNzlPaXVZWjhJdHhCNXQtSzFJZHl0SW5iaWo1bllSbmVTVFRvdVVTakg3T3FNMlFRRm91YzBaMUtNdFJYOTJmOUVhaUxVV3VqbXg5N2hNOGpadm9TM3UtMmZBRUhlVlhuR01Oc1ZoQQ?oc=5","date":"2025-10-17","type":"pipeline","source":"fortunebusinessinsights.com","summary":"U.K. Pharmaceuticals Market Size, Share | Growth Report [2032] - fortunebusinessinsights.com","headline":"U.K. Pharmaceuticals Market Size, Share | Growth Report [2032]","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiuAFBVV95cUxONE5PYlJmd0ZxS0c3WDR2NnB1d0hLZWtET3dDQm1FbGZ2WkZyV3d6aXJOdHZxSU83RlJRUzRKTVNIVURRR1VCeDgwVzRHaTlOVXd4dzlJVkVneVliVDdCdmpIUkNIUUZoVHdtQUhtRXRCMkk2YU5DbWhxY0NNY3hKdFktS0ExR0FuTzVoZ1FObEJkWHNIWDZMM3drZk5HdXExbzlDZWE4QnZHUlhyc21OeFBnTnR1R25I0gG-AUFVX3lxTE5YWWlFWnF1MkNVdm5HYXgwQXBCbzF0dHA5Qk5PbEdkVGRVcXMya3BzeTduZjlPVVRDeERrY21LRHRyS2xyaFZrY0RfVzFkUTN2R2hzMDBoV2FkQVJtNVc4STgwQm9GTi0xQzlNVnc3S0dXeVJfOHFiLWJMZUNOWGRVMGlTWmhTZXBNWlNhNllUWmwtb3EwSHpEUDhTTlNtbGNCS2ZCajdmLThEeW95ei1kaG1WWjFTYkZCLVdja3c?oc=5","date":"2025-07-07","type":"pipeline","source":"medicaldialogues.in","summary":"Biocon Biologics gets marketing nods in UK for Vevzuo, Evfraxy - medicaldialogues.in","headline":"Biocon Biologics gets marketing nods in UK for Vevzuo, Evfraxy","sentiment":"neutral"},{"url":"https://news.google.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?oc=5","date":"2025-07-07","type":"patent","source":"The Economic Times","summary":"Biocon Biologics gets UK MHRA nod for biosimilars Vevzuo, Evfraxy - The Economic Times","headline":"Biocon Biologics gets UK MHRA nod for biosimilars Vevzuo, Evfraxy","sentiment":"neutral"},{"url":"https://news.google.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?oc=5","date":"2025-05-26","type":"patent","source":"ET Pharma","summary":"Biocon Biologics psoriasis biosimilar receives UK regulator nod - ET Pharma","headline":"Biocon Biologics psoriasis biosimilar receives UK regulator nod","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiWEFVX3lxTE95dUpkc1RUazlvODhfc2oxMklWMkYyX2VlS0JTLUtMZmVReHMwVWxkdzJ4cTZudEJUU0c1bnBwbEJfcnF6SXA4TEF3NC14UjQ4N1VRRXNIMlo?oc=5","date":"2025-05-08","type":"earnings","source":"Biocon","summary":"Biocon Q4FY25 Revenue at Rs 4,454 Cr, Up 15%** EBITDA at Rs 1,115 Cr; Up 16%; Net Profit at Rs 344 Cr, Up 153% - Biocon","headline":"Biocon Q4FY25 Revenue at Rs 4,454 Cr, Up 15%** EBITDA at Rs 1,115 Cr; Up 16%; Net Profit at Rs 344 Cr, Up 153%","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMioAFBVV95cUxPdUJud0piUjRCQnpVV1VCSy1zSklZSmNFU0hSalRRaTVqb01QTjFzQ1AzRlB2elJHRDdnLWJRejV6czNad0FiVGpyWExRRmo5M1RqRXE2cGVBNUVyXzVudmk4MlpjRHdESnh1TjVDOE84LV9Cc0NXOTdjbS15a2xhRjI4QTd5SE81VVg2bXNEeXdmRjltMXNGR0V4R1ZoYm1U?oc=5","date":"2024-01-23","type":"patent","source":"Generics and Biosimilars Initiative","summary":"Biocon to commercialize biosimilars in 31 European countries - Generics and Biosimilars Initiative","headline":"Biocon to commercialize biosimilars in 31 European countries","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMivAFBVV95cUxPd3JtQkVOcENCYVVSbGNqaFplenJYRHRNTzlITkpXZFltUWp6R3F2SjFGWURGdWp4a1VIaFBMdDVRZG9SUG5WVFE3cGJRVUlGTGJKOXpoWkdNTERYQXRjbmtsTko5aHZDd0dTNFN6aWlEbS1mc0xWT0w5b0Z6X1p1N3Qxdk15RjdqbkFiYjNraUNaNUhXUFItMXFFckRxMVExMEV6NlhwRHFaNmRBcTVzWWlsY25zaUhER1o0RQ?oc=5","date":"2023-11-13","type":"regulatory","source":"Ophthalmology Times Europe","summary":"MHRA issues UK marketing approval for Biocon Biologics biosimilar aflibercept (YESAFILI®) - Ophthalmology Times Europe","headline":"MHRA issues UK marketing approval for Biocon Biologics biosimilar aflibercept (YESAFILI®)","sentiment":"positive"}],"patents":[],"drugCount":4,"phaseCounts":{"marketed":2,"phase_3":2},"enrichmentLevel":0,"visitCount":2,"keyCompetitors":[],"therapeuticFocus":[],"financials":null,"yahoo":null}